Percutaneous Coronary Intervention in Diabetic Patients: A Problem?

Abstract

Pharmacological and technological advances in surgical and interventional coronary treatment modalities have shown reduced cardiovascular mortality in non-diabetic patients, but diabetic patients have not gained the same benefit of invasive treatment as non-diabetics. Although early studies suggest a poorer outcome after angioplasty than after coronary by-pass grafting (CABG) in diabetic patients, more recent studies including improved pharmacological therapy and stent implantation seem to justify increased use of revascularization by percutaneous coronary intervention (PCI) in diabetics with stable and unstable coronary syndromes as the relative benefit in long-term survival, non-fatal myocardial infarction and cerebrovascular accidents is similar. However, diabetic patients are still subject to higher morbidity and mortality after revascularization with CABG and PCI. This is related to increased co-morbidity, metabolic dysregulation, difficulties in obtaining complete revascularization, and more frequent appearance of new lesions as well as restenosis and hemostatic abnormalities. Drug-eluting stents appear to reduce the risk of restenosis, and aggressive antithrombotics also tend to improve the outcome. Unsolved problems are the significance of incomplete revascularization and whether a PCI strategy is associated with a procedure induced progression of the native diabetic vascular disease in treated or untreated vessels. Trials addressing adjunctive treatment and long-term clinical outcome specifically in diabetic patients should clarify these questions.

Key words

Diabetes mellitus · Percutaneous coronary intervention · Angioplasty · Stent

References

• 1 Laskey W K, Selzer F, Vlachos H A, Johnston J, Jacobs A, King S B III. et al . Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry).  Am J Cardiol. 2002;  90 1062-1067
• 2 Mehran R, Dangas G D, Kobayashi Y, Lansky A J, Mintz G S, Aymong E D. et al . Short- and long-term results after multivessel stenting in diabetic patients.  J Am Coll Cardiol. 2004;  43 1348-1354
• 3 Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N. et al . Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.  Circulation. 2004;  110 3627-3635
• 4 Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi M I, Palacios I F. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group.  J Am Coll Cardiol. 1993;  22 1060-1067
• 5 King S B III, Lembo N J, Weintraub W S, Kosinski A S, Barnhart H X, Kutner M H. et al . A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST).  N Engl J Med. 1994;  331 1044-1050
• 6 First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants.  Lancet. 1995;  346 1179-1184
• 7 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.  N Engl J Med. 1996;  335 217-225
• 8 Serruys P W, Unger F, Sousa J E, Jatene A, Bonnier H J, Schonberger J P. et al . Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.  N Engl J Med. 2001;  344 1117-1124
• 9 Nallamothu B K, Shojania K G, Saint S, Hofer T P, Humes H D, Moscucci M. et al . Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.  Am J Med. 2004;  117 938-947
• 10 Murphy S W, Barrett B J, Parfrey P S. Contrast nephropathy.  J Am Soc Nephrol. 2000;  11 177-182
• 11 Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K. et al . Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.  J Am Coll Cardiol. 2003;  41 1-7
• 12 Corpus R A, George P B, House J A, Dixon S R, Ajluni S C, Devlin W H. et al . Optimal glycaemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention.  J Am Coll Cardiol. 2004;  43 8-14
• 13 Mazeika P, Prasad N, Bui S, Seidelin P H. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus.  Am Heart J. 2003;  145 1013-1021
• 14 Shanmugam N, Reddy M A, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells.  Diabetes. 2003;  52 1256-1264
• 15 Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S. et al . Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.  J Am Coll Cardiol. 2000;  36 1529-1535
• 16 Caballero A E, Saouaf R, Lim S C, Hamdy O, Abou-Elenin K, O’Connor C. et al . The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.  Metabolism. 2003;  52 173-180
• 17 Wang C H, Ciliberti N, Li S H, Szmitko P E, Weisel R D, Fedak P W. et al . Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.  Circulation. 2004;  109 1392-1400
• 18 Nathan D M, Lachin J, Cleary P, Orchard T, Brillon D J, Backlund J Y. et al . Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.  N Engl J Med. 2003;  348 2294-2303
• 19 van der Horst I CC, Zijlstra F, van’t Hof A W, Doggen C J, de Boer M J, Suryapranata H. et al . Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial.  J Am Coll Cardiol. 2003;  42 784-791
• 20 Pache J, Kastrati A, Mehilli J, Bollwein H, Ndrepepa G, Schuhlen H. et al . A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy.  Am Heart J. 2004;  148 e3
• 21 Mehta R H, Harjai K J, Cox D, Stone G W, Brodie B, Boura J. et al . Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention.  J Am Coll Cardiol. 2003;  42 1739-1746
• 22 Rozenman Y, Sapoznikov D, Mosseri M, Gilon D, Lotan C, Nassar H. et al . Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation.  J Am Coll Cardiol. 1997;  30 1420-1425
• 23 Kornowski R, Hong M K, Tio F O, Bramwell O, Wu H, Leon M B. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia.  J Am Coll Cardiol. 1998;  31 224-230
• 24 Farb A, Weber D K, Kolodgie F D, Burke A P, Virmani R. Morphological predictors of restenosis after coronary stenting in humans.  Circulation. 2002;  105 2974-2980
• 25 Holmes D R Jr, Vlietstra R E, Smith H C, Vetrovec G W, Kent K M, Cowley M J. et al . Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute.  Am J Cardiol. 1984;  53 77C-81C
• 26 Kornowski R, Mintz G S, Kent K M, Pichard A D, Satler L F, Bucher T A. et al . Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study.  Circulation. 1997;  95 1366-1369
• 27 Abizaid A, Kornowski R, Mintz G S, Hong M K, Abizaid A S, Mehran R. et al . The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.  J Am Coll Cardiol. 1998;  32 584-589
• 28 Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J. et al . Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.  J Am Coll Cardiol. 1998;  32 1866-1873
• 29 Abizaid A, Costa M A, Centemero M, Abizaid A S, Legrand V M, Limet R V. et al . Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.  Circulation. 2001;  104 533-538
• 30 Morice M C, Serruys P W, Sousa J E, Fajadet J, Ban H E, Perin M. et al . A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.  N Engl J Med. 2002;  346 1773-1780
• 31 Moses J W, Leon M B, Popma J J, Fitzgerald P J, Holmes D R, O’Shaughnessy C. et al . Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.  N Engl J Med. 2003;  349 1315-1323
• 32 Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S. et al . Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.  Circulation. 2003;  108 788-794
• 33 Schofer J, Schluter M, Gershlick A H, Wijns W, Garcia E, Schampaert E. et al . Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).  Lancet. 2003;  362 1093-1099
• 34 Moussa I, Leon M B, Baim D S, O’Neill W W, Popma J J, Buchbinder M. et al . Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.  Circulation. 2004;  109 2273-2278
• 35 Dawkins K. TAXUS VI: Angiographic results and QCA analysis. Paris; Euro PCR 2004 2004
• 36 Scheen A J, Warzee F, Legrand V M. Drug-eluting stents: meta-analysis in diabetic patients.  Eur Heart J. 2004;  25 2167-2168
• 37 Abizaid A, Costa M A, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G. et al . Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial.  Eur Heart J. 2004;  25 107-112
• 38 Stone G W, Ellis S G, Cox D A, Hermiller J, O’Shaughnessy C, Mann J T. et al . One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.  Circulation. 2004;  109 1942-1947
• 39 Lemos P A, Serruys P W, van Domburg R T, Saia F, Arampatzis C A, Hoye A. et al . Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the ”real world”: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.  Circulation. 2004;  109 190-195
• 40 Mathew V, Gersh B J, Williams B A, Laskey W K, Willerson J T, Tilbury R T. et al . Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.  Circulation. 2004;  109 476-480
• 41 Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI).  Circulation. 1997;  96 1761-1769
• 42 Colwell J A, Nesto R W. The platelet in diabetes: focus on prevention of ischemic events.  Diabetes Care. 2003;  26 2181-2188
• 43 The EPISTENT Investigators . Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.  Lancet. 1998;  352 87-92
• 44 Roffi M, Chew D P, Mukherjee D, Bhatt D L, White J A, Heeschen C. et al . Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.  Circulation. 2001;  104 2767-2771
• 45 Lincoff A M. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade.  Circulation. 2003;  107 1556-1559
• 46 Vaccarino V, Parsons L, Every N R, Barron H V, Krumholz H M. Impact of history of diabetes mellitus on hospital mortality in men and women with first acute myocardial infarction. The National Registry of Myocardial Infarction 2 Participants.  Am J Cardiol. 2000;  85 1486-1489
• 47 Mukamal K J, Nesto R W, Cohen M C, Muller J E, Maclure M, Sherwood J B. et al . Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction.  Diabetes Care. 2001;  24 1422-1427
• 48 Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L. et al . Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.  J Am Coll Cardiol. 2004;  43 585-591
• 49 Fox K A, Poole-Wilson P A, Henderson R A, Clayton T C, Chamberlain D A, Shaw T R. et al . Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina.  Lancet. 2002;  360 743-751
• 50 Cannon C P, Weintraub W S, Demopoulos L A, Vicari R, Frey M J, Lakkis N. et al . Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.  N Engl J Med. 2001;  344 1879-1887
• 51 Keeley E C, Boura J A, Grines C L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.  Lancet. 2003;  361 13-20
• 52 Andersen H R, Nielsen T T, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P. et al . A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.  N Engl J Med. 2003;  349 733-742
• 53 Grines C, Patel A, Zijlstra F, Weaver W D, Granger C, Simes R J. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials.  Am Heart J. 2003;  145 47-57
• 54 Hasdai D, Granger C B, Srivatsa S S, Criger D A, Ellis S G, Califf R M. et al . Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes.  J Am Coll Cardiol. 2000;  35 1502-1512
• 55 Boersma E, Simes R J, Grines C L, Westerhouf C M. Does time matter? Individual patient data-based meta-analysis of primary PCI versus fibrinolysis in acute myocardial infarction randomized trials.  Circulation Suppl. 2004;  110 III-539
• 56 Madsen M M, Busk M, Søndergaard H M, Bottcher M, Mortensen L S, Andersen H R. et al .Does diabetes mellitus abolish the beneficial effect of primary angioplasty on long-term risk of reinfarction after acute ST-segment elevation infarction?. Submitted 2005
• 57 Biondi-Zoccai G G, Abbate A, Liuzzo G, Biasucci L M. Atherothrombosis, inflammation, and diabetes.  J Am Coll Cardiol. 2003;  41 1071-1077
• 58 Granger C B, Mahaffey K W, Weaver W D, Theroux P, Hochman J S, Filloon T G. et al . Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.  Circulation. 2003;  108 1184-1190